Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 September 2026
Filed with HKEX · Stock code 8158 · · 10 pages · English
Summary by 6ix AI
It confirms the total authorized share capital and provides details on issued shares and public float sufficiency. The report indicates that the number of issued shares remained unchanged during the month. Additionally, it includes confirmations regarding compliance with listing rules and other regulatory requirements.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
China Regenerative Medicine International Limited on 6ix
Earlier from China Regenerative Medicine International
- Letter to Non-registered Shareholder - New Arrangements on Dissemination of Corporate Communications
- Letter to Registered Shareholder - New Arrangements on Dissemination of Corporate Communications and Reply Form
- Interim Report 2026
- CEO Mr. Chen Chunguo Holds a Meeting with Government Official of Shaanxi Xixian New Area - Discuss the Strategic Deployment of Regenerative Medicine Industry Develop Hi-tech Cosmeceuticals Industrial Park
- R&D Team of “Acornea” Invited to Share the R&D and Application Experience of the First Chinese Bio- engineered Cornea at Oxford
Follow China Regenerative Medicine International into a list and get an email when it puts out news.
Follow China Regenerative Medicine International